Join our daily newsletter At The Bell to receive exclusive market insights
- Orthocell’s (OCC) shoulder tendon study database has been locked, with the study data submitted for analysis
- The company’s rotator cuff tendon study (RC Study) was designed to assess the effectiveness of its Autologous Tenocyte Injection (Ortho-ATI) when compared to corticosteroids, as a nonsurgical treatment
- Locking the Ortho-ATI RC study indicates the data has been verified by the clinical investigators and cannot be altered
- The data has been submitted for analysis, and the company says it’s on track for reporting top line results in the fourth quarter of 2021
- Orthocell shares were up 8.08 per cent, trading at 53.5 cents at 12:55 pm AEDT
Orthocell’s (OCC) shoulder tendon study database has been locked, with the study data submitted for analysis.
The company’s rotator cuff tendon study (RC Study) was designed to assess the effectiveness of its Autologous Tenocyte Injection (Ortho-ATI) when compared to corticosteroids as a nonsurgical treatment.
Currently, there are no proven long-term, non-surgical solutions to repair chronic shoulder tendon injuries. Expensive surgical options are available, but its effectiveness is not guaranteed and additional rehabilitation is required.
If Orthocell’s shoulder tendon study meets its objectives, it will become the first randomised cellular therapy study successfully completed for this indication anywhere in the world.
The company said this would also place Orthocell in a strong position to progress its US commercialisation strategy to deliver the first injectable cell therapy in orthopaedics for the treatment of chronic tendon injuries.
Locking the Ortho-ATI RC study indicates the data has been verified by the clinical investigators and cannot be altered.
The data has been submitted for analysis, and the company said it’s on track for reporting top line results in the fourth quarter of 2021.
Orthocell shares were up 8.08 per cent, trading at 53.5 cents at 12:55 pm AEDT.
